Clinical trial NCT01400555: A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Official title: A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Prostate Neoplasms
Prostate Cancer
Keywords: Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Abiraterone Acetate
Docetaxel
Prednisone
Dexamethasone
Lead sponsor: Cougar Biotechnology, Inc.
Sponsor class: INDUSTRY
First posted: 2011-07-22
Enrollment: 22
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the maximum safe dose of abiraterone acetate administered in combination with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Detailed description: This is an open-label (patients and their doctors will know the identity of study drug administered), uncontrolled (patients are not assigned to treatment by chance), multicenter safety study of escalating dose levels of abiraterone acetate administered in combination with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). This study is conducted in 2 parts. Part I consists of Screening, Treatment, assessment of dose-limiting toxicity (DLT), and determination of the maximum tolerated dose (MTD). Participants are enrolled in sequential 6-subject cohorts (groups) and administered combination therapy (abiraterone acetate and docetaxel plus prednisone) according to a dose-escalation schedule. The abiraterone acetate dose in this study will escalate from 500 mg to 1000 mg daily until the MTD is determined. The MTD is the highest combination dose among the dose combinations investigated in this study at which no more than 2 (33%) of the patients in a cohort experience a DLT. A DLT is defined by an adverse event occurring from Day 1 Week 2 (first dose of abiraterone acetate) to the day before the Day 1 Week 7 docetaxel infusion (3 weeks after the second docetaxel infusion); non-hematological toxicity \>=Grade 3; Grade 4 neutropenia lasting more than 5 days, neutropenia complicated by fever, or systemic infection; thrombocytopenia \<25,000/mcL, or any thrombocytopenia requiring platelet transfusion; and, any subjectively intolerable toxicity. Part II of the study consists of Continuing Treatment, when patients remain at the allocated dose level, escalate to the combination MTD, or discontinuation of docetaxel (if toxicity or intolerability develops) and continue abiraterone acetate (up to 1000 mg/day) plus prednisone, until disease progression; End of Treatment, when posttreatment efficacy and safety will be documented; and Follow-Up, when survival status and new antitumor therapy are monitored. Blood samples for pharmacokinetic and efficacy measurements will be collected at selected times during the study. Safety will be monitored. The total duration of study participation may be up to 36 months. Oral abiraterone acetate will be administered as a single daily dose (500, 750, or 1000 mg). Docetaxel will be administered once every 3 weeks as an intravenous (IV) infusion (60 or 75 mg/m2) over 1 hour. Study participants will premedicate with oral dexamethasone 8 mg 1, 3, and 12 hours before the start of each docetaxel IV infusion. Oral prednisone 5 mg will be administered twice daily.

Eligibility criteria: Inclusion Criteria:

* Adenocarcinoma of the prostate
* Metastatic disease documented by bone, computed tomography (CT), or magnetic resonance image (MRI) scan
* Surgical or medical castration with testosterone less than 50 ng/dL
* Prostate cancer progression documented by 1 of the following: PSA progression according to Prostate Cancer Working Group 2 (PCWG2) criteria, radiographic progression by modified Response Evaluation Criteria in Solid Tumors (RECIST) or bone scan
* Absolute neutrophil count \>1,500 cells/mm3
* Platelets \>100,000/µl
* Hemoglobin \>=10.0 g/dL
* Eastern Cooperative Group (ECOG) status score of \<=2.

Exclusion Criteria:

* Elevated liver function tests (LFTs): Serum bilirubin \>upper limit of normal (ULN), alanine (ALT) or aspartate (AST) aminotransferase \> 1.5 ULN concomitant with alkaline phosphatase \> 2.5 ULN
* Small cell carcinoma of the prostate
* Pulmonary or brain metastasis, liver metastasis is allowed if LFTs are not elevated
* Pre-existing neuropathy or severe fluid retention
* Prior cytotoxic chemotherapy for metastatic prostate cancer
* Prior therapy with other CYP17 inhibitor(s) or investigational agent(s) targeting the androgen receptor for metastatic prostate cancer
* Treatment of primary tumor within 4 weeks of Day 1 Week 1 with surgery, radiation, chemotherapy or immunotherapy
* Use of investigational drug within 4 weeks of Day 1 Week 1 or current enrollment in an investigational drug or device study
* Prior ketoconazole for prostate cancer
* Recent history of ischemic heart disease, electrocardiogram (ECG) abnormalities, or atrial fibrillation.

Primary outcomes:
measure: Proportion of patients with a dose-limiting toxicity
timeFrame: Up through Week 6
Secondary outcomes:
measure: Proportion of patients with prostate-specific antigen (PSA) response
timeFrame: Up to Month 36
measure: Time to PSA progression
timeFrame: Up to Month 36
measure: Objective response rate
timeFrame: Up to Month 36
measure: Radiographic progression-free survival
timeFrame: Up to Month 36
measure: Survival
timeFrame: Up to Month 36
Other outcomes:
Locations:
city: Los Angeles
country: United States
state: California
city: New York
country: United States
state: New York
city: Madison
country: United States
state: Wisconsin
Study officials:
affiliation: Cougar Biotechnology, Inc.
name: Cougar Biotechnology, Inc. Clinical Trial
role: STUDY_DIRECTOR
References:
citation: Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 2012 Jul 2;5:35. doi: 10.1186/1756-8722-5-35.